Get the Stockscreener App
42.40
0.19%
-0.08
Taro Pharmaceutical Industries stock is currently priced at $42.40, with a 24-hour trading volume of 26,816.
It has seen a -0.19% decreased in the last 24 hours and a +0.62% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $42.37 pivot point. If it approaches the $42.60 resistance level, significant changes may occur.
Previous Close:
$42.48
Open:
$42.34
24h Volume:
26,816
Market Cap:
$1.59B
Revenue:
$610.83M
Net Income/Loss:
$45.70M
P/E Ratio:
69.51
EPS:
0.61
Net Cash Flow:
$86.00M
1W Performance:
+0.36%
1M Performance:
+0.62%
6M Performance:
+26.42%
1Y Performance:
+67.66%
1D Range:
$42.23
$42.49
52W Range:
$24.69
$45.76
Taro Pharmaceutical Industries Stock (TARO) Company Profile
Name
Taro Pharmaceutical Industries
Sector
Phone
972 4 847 5700
Address
14 Hakitor Street, Haifa Bay, Haifa
Taro Pharmaceutical Industries Stock (TARO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-27-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-04-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Initiated | H.C. Wainwright | Buy |
| May-23-17 | Downgrade | Credit Suisse | Outperform → Neutral |
View All
Taro Pharmaceutical Industries Stock (TARO) Latest News
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Zacks Investment Research
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
Zacks Investment Research
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Zacks Investment Research
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
Zacks Investment Research
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Zacks Investment Research
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
Zacks Investment Research
Taro Pharmaceutical Industries Stock (TARO) Financials Data
Taro Pharmaceutical Industries (TARO) Revenue 2024
TARO reported a revenue (TTM) of $610.83 million for the quarter ending December 31, 2023, a +7.23% rise year-over-year.
Taro Pharmaceutical Industries (TARO) Net Income 2024
TARO net income (TTM) was $45.70 million for the quarter ending December 31, 2023, a -0.51% decrease year-over-year.
Taro Pharmaceutical Industries (TARO) Cash Flow 2024
TARO recorded a free cash flow (TTM) of $86.00 million for the quarter ending December 31, 2023, a +188.64% increase year-over-year.
Taro Pharmaceutical Industries (TARO) Earnings per Share 2024
TARO earnings per share (TTM) was $1.22 for the quarter ending December 31, 2023, a 0.00% decline year-over-year.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.
1.69%
1.28%
Cap:
|
Volume (24h):